Ignite Creation Date:
2024-05-06 @ 3:26 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02280785
Status:
COMPLETED
Last Update Posted:
2018-09-06
First Post:
2014-10-05
Brief Title:
Brentuximab Vedotin for RelapsedRefractory CD30-positive Non-Hodgkin Lymphomas
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Organization Data
Organization:
Samsung Medical Center
Class:
OTHER
Study ID:
SMC 2014-04-059
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Samsung Medical Center
Lead Sponsor Class:
OTHER
Responsible Party:
Won Seog Kim
Responsible Party Title:
A phase II study of Brentuximab Vedotin for relapsedrefractory CD30-positive non-Hodgkin lymphomas other than anaplastic large cell lymphoma
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Samsung Medical Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Millennium Pharmaceuticals Inc | INDUSTRY |